RVTY
NYSE · USDRevvity, Inc.
Healthcare · Medical - Diagnostics & Research
CEO Prahlad R. Singh
Employees 11,000
R&D / revenue 7.6%
Last price
$152.64−1.34%last session
Market cap
$17.0B
P/E (TTM)
72.7x
From 52w high
−8.2%
From 52w low
+87.9%
1-year return
+62.5%
RSI 14 · vs SMA200
59.2 · +39.9%
IS score
50.5/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)
One year, rebased to 100
RVTY SPY XLV (sector ETF) · weekly closesScore DNA
Each bar is a 0-100 score within the scored universe35Profitability
34Growth
40Value
66Momentum
65Risk (safety)
70Quality
55Balance sheet
69Earnings quality
Flags
Strengths
✓ Congress buying
Warnings
None of the computed warning flags fires for RVTY (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Efficient ScalePiotroski 6 / 9Altman Z 2.7Beta 1.093 of 4 smart-money sources active
Smart-money strip
Each disclosure source on its own window. Filings coinciding is not coordination.INSForm 4 · 180 days
Insider open-market buys
0
5 open-market sales, $1.3M
Form 144 notices (12m): 10, $6.0M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
4
Last disclosed purchase 2026-05-04
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+545
102 new holders, 55 closed
545 filers hold 103.0% · 198 added, 165 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+67
281 funds adding shares
214 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
55.6%
20-day avg 52.3%, 50-day avg 51.1%
Latest 3.3 pp over its 20-day average · a flow, not short interest
Key financials · FY2025
USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.Income statement
Revenue$2.9B
Revenue growth YoY+3.7%
Gross margin53.1%
Operating income$356.6M
Operating margin12.5%
Net income$241.7M
Net margin8.5%
EPS (diluted)$2.08
Cash flow
Operating cash flow$581.8M
Capital expenditure$73.5M
Free cash flow$508.3M
FCF conversion (FCF / OCF)87.4%
Stock-based compensation$22.8M
FCF less SBC$485.4M
Buybacks$820.8M
Dividends$32.8M
Balance sheet & returns
Cash & short-term investments$919.9M
Total debt$3.4B
Net debt$2.4B
Shareholders' equity$7.3B
Goodwill & intangibles$9.0B
Debt / equity0.46
ROE (TTM)3.3%
ROIC (TTM)2.9%
Operating margin by fiscal year
Revenue $3.8B (FY2021) to $2.9B (FY2025), a -7.1% CAGR.
Valuation
P/E (TTM)72.7x
EV / EBITDA25.2x
Price / sales5.85x
Price / FCF30.5x
FCF yield3.28%
Buyback yield4.82%
SBC / revenue0.8%
Price / book2.36x
Forward P/E FY202628.5x
Forward P/E FY202628.7x
Forward P/E FY202725.9x
Forward multiples divide today's price by Street EPS estimates. Street mean target $150.00 across 4 analysts last quarter is theirs, not ours.
RVTY vs industry median
126 companies in Medical - Diagnostics & Research
RVTY (TTM)Industry median
Asset turnover 0.24 vs industry 0.54 · financial leverage 1.67
Earnings delivery
Next report 2026-11-03 · consensus EPS $1.3092%
beat rate, 11 of 12 quarters
+4.6%
median EPS surprise
11
longest beat streak
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-30 to 2026-08-04. Bars cap at ±60%.
Peers
Market-cap band, not the industry cohort above| Company | Mkt cap | P/E | ROE | Net margin | Rev growth | 12m return |
|---|---|---|---|---|---|---|
| RVTY Revvity, Inc. | $17.0B | 72.7x | 3.3% | 8.2% | +3.7% | +62.5% |
| MEDP Medpace Holdings, Inc. | $17.3B | 35.6x | 162.2% | 17.2% | +24.7% | +18.7% |
| EXAS Exact Sciences Corporation | $20.0B | n/m | -8.7% | -9.8% | +17.7% | +96.4% |
| CRL Charles River Laboratories I | $14.5B | n/m | -7.7% | -0.1% | −0.7% | +71.6% |
| GH Guardant Health, Inc. | $21.3B | n/m | 171.6% | -35.9% | +42.7% | +135.1% |
| ICLR ICON Public Limited Company | $13.1B | 39.7x | 3.5% | 3.5% | +2.0% | — |
| LH Labcorp Holdings Inc. | $25.8B | 26.1x | 11.7% | 8.0% | +6.4% | — |
| DGX Quest Diagnostics Incorporat | $25.9B | 24.6x | 14.4% | 10.5% | +9.9% | — |
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.
Recent 8-K filings
2026-08-04Earnings Release; Other Events; Exhibits
2026-05-05Earnings Release; Other Events; Exhibits
2026-05-01Bylaws Amendment; Shareholder Vote; Exhibits
2026-02-02Results of Operations and Financial Condition; Financial Statements and Exhibits
2026-01-13Results of Operations and Financial Condition; Regulation FD Disclosure
2025-10-27Results of Operations and Financial Condition; Financial Statements and Exhibits
Context
Shares outstanding111,586,000
Free float91.9%
Institutional ownership103.0%
Beta1.09
Dividend yield0.18%
Last dividend$0.07 on 2026-10-23
50 / 200-day average$135.36 / $108.84
Large-cap Healthcare median P/E29.7x
Full factsheet
The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).
Read it in the browser Download (PDF)All fundamentals · 140 measures in 13 categories
Percentile = where RVTY sits among 30 scored companies in Medical - Diagnostics & Research (0 = lowest value, 100 = highest). It is a position, not a grade.ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)
Valuation
| Measure | RVTY | Industry percentile |
|---|---|---|
| P/E (TTM) | 71.7x | 88th |
| PEG (P/E ÷ 3-yr EPS CAGR) | — | |
| Price / sales | 5.8x | 52nd |
| Price / book | 2.4x | 22nd |
| Price / tangible book | — | |
| Price / free cash flow | 30.5x | 42nd |
| Price / operating cash flow | 27.1x | 52nd |
| Enterprise value | $19.4B | 59th |
| EV / sales | 6.6x | 62nd |
| EV / EBITDA | 25.2x | 48th |
| EV / EBIT | 54.5x | 82nd |
| EV / free cash flow | 34.6x | 42nd |
| Earnings yield | 1.4% | 48th |
| FCF yield | 3.3% | 72nd |
| Operating cash flow yield | 3.7% | 59th |
| Graham number (per share) | $55.63 | 47th |
Profitability (TTM)
| Measure | RVTY | Industry percentile |
|---|---|---|
| Gross margin | 52.1% | 48th |
| EBITDA margin | 26.3% | 76th |
| Operating margin | 12.3% | 55th |
| EBIT margin | 12.2% | 59th |
| Net margin | 8.2% | 55th |
| NOPAT margin | 11.3% | 62nd |
| FCF margin | 19.2% | 72nd |
| Operating cash flow margin | 21.6% | 69th |
| R&D / revenue | 7.4% | 52nd |
| SG&A / revenue | 32.4% | 55th |
| Stock comp / revenue | 0.8% | 14th |
| Effective tax rate | 8.0% | 14th |
Returns on capital
| Measure | RVTY | Industry percentile |
|---|---|---|
| ROE (on average equity) | 3.2% | 44th |
| ROA | 1.9% | 45th |
| ROIC | 3.5% | 45th |
| ROCE | 3.3% | 48th |
| Return on tangible assets | 2.9% | 48th |
| Cash ROIC (OCF / invested capital) | 6.6% | 31st |
| Gross profitability (GP / assets) | 12.6% | 24th |
| ROIC, 3-yr average | 2.6% | 46th |
| ROIC, 5-yr average | 6.0% | 58th |
| ROE, 5-yr average | 6.9% | 60th |
| Incremental ROIC | -22.7% | 37th |
Growth
| Measure | RVTY | Industry percentile |
|---|---|---|
| Revenue growth (TTM YoY) | 5.5% | 32nd |
| Revenue growth (QoQ) | 2.6% | 21st |
| Revenue CAGR, 3 yr | -3.6% | 4th |
| Revenue CAGR, 5 yr | -5.1% | 7th |
| Gross profit CAGR, 3 yr | -6.9% | 11th |
| Operating income CAGR, 3 yr | -21.5% | 7th |
| Net income growth (TTM YoY) | -11.9% | 19th |
| Net income CAGR, 3 yr | -38.0% | 0th |
| EPS growth (TTM YoY) | -7.4% | 19th |
| EPS CAGR, 3 yr | -35.4% | 8th |
| EPS CAGR, 5 yr | -20.0% | 7th |
| FCF growth (TTM YoY) | 14.2% | 56th |
| FCF CAGR, 3 yr | 2.2% | 29th |
| Operating cash flow CAGR, 3 yr | 1.4% | 29th |
| Book value CAGR, 3 yr | 0.6% | 36th |
| Dividend CAGR, 3 yr | 1.9% | 0th |
| Sustainable growth rate | 2.8% | 6th |
Margin history & stability
| Measure | RVTY | Industry percentile |
|---|---|---|
| Gross margin, 3-yr average | 52.8% | 46th |
| Operating margin, 3-yr average | 13.4% | 61st |
| Net margin, 3-yr average | 8.1% | 64th |
| FCF margin, 3-yr average | 13.5% | 61st |
| Revenue stability (0-1) | 0.74 | 43rd |
| Earnings stability (0-1) | 0.57 | 64th |
| Margin stability (0-1) | 0.95 | 61st |
Liquidity (latest quarter)
| Measure | RVTY | Industry percentile |
|---|---|---|
| Cash & short-term investments | $1.0B | 76th |
| Net cash (− = net debt) | −$2.3B | 28th |
| Working capital | $1.0B | 66th |
| Current ratio | 1.80 | 41st |
| Quick ratio | 1.50 | 41st |
| Cash ratio (cash + ST investments / current liabilities) | 0.80 | 45th |
| Defensive interval (days) | 546 days | 62nd |
Leverage & solvency (latest quarter)
| Measure | RVTY | Industry percentile |
|---|---|---|
| Total debt | $3.3B | 72nd |
| Debt / equity | 0.46 | 44th |
| Net debt / equity | 0.32 | 59th |
| Debt / assets | 27.7% | 41st |
| Debt / capital | 31.6% | 43rd |
| Debt / EBITDA | 4.36 | 71st |
| Net debt / EBITDA | 3.02 | 57th |
| Interest coverage (EBIT / interest) | 3.8x | 60th |
| Cash interest coverage | 6.7x | 48th |
| Debt payback (years of OCF) | 5.3 yrs | 74th |
| Liabilities / assets | 40.0% | 34th |
| IS credit model rating | A- | |
| Implied credit spread (bps) | 175 | 45th |
Efficiency
| Measure | RVTY | Industry percentile |
|---|---|---|
| Asset turnover | 0.24 | 3rd |
| Fixed asset turnover | 4.80 | 62nd |
| Inventory turnover | 3.6 | 20th |
| Receivables turnover | 4.2 | 10th |
| Days sales outstanding | 86 days | 90th |
| Days inventory outstanding | 100 days | 80th |
| Days payables outstanding | 45 days | 52nd |
| Cash conversion cycle (days) | 141 days | 90th |
| Capex / revenue | 2.4% | 28th |
| Capex / depreciation | 0.17 | 7th |
| Operating expense ratio | 44.9% | 48th |
Cash flow & earnings quality
| Measure | RVTY | Industry percentile |
|---|---|---|
| Operating cash flow / net income | 2.65 | 88th |
| FCF / net income | 2.35 | 88th |
| FCF / operating cash flow | 88.9% | 74th |
| Capex / operating cash flow | 11.1% | 26th |
| Accruals ratio | -3.2% | 69th |
| Sloan accruals ratio | -7.8% | 14th |
| Earnings quality score (0-1) | 1.00 | 24th |
Scores & forensic checks
| Measure | RVTY | Industry percentile |
|---|---|---|
| IS score | 50 | 52nd |
| IS profitability | 35 | 48th |
| IS growth | 34 | 14th |
| IS value | 40 | 48th |
| IS momentum | 66 | 39th |
| IS risk (safety) | 65 | 34th |
| IS quality | 70 | 62nd |
| IS balance sheet | 55 | 62nd |
| IS earnings quality | 69 | 52nd |
| IS cash flow | 69 | 72nd |
| Piotroski F-score (0-9) | 6 | 41st |
| Altman Z-score | 2.7 | 34th |
| Beneish M-score | −2.62 | 46th |
| Ohlson O-score | −8.69 | 34th |
| IS credit score | 65 | 48th |
Size (TTM)
| Measure | RVTY | Industry percentile |
|---|---|---|
| Market cap | $17.0B | 55th |
| Revenue | $2.9B | 59th |
| EBITDA | $767.0M | 59th |
| Net income | $237.6M | 59th |
| Free cash flow | $559.3M | 62nd |
| Total assets | $12.0B | 72nd |
| Shareholders' equity | $7.2B | 76th |
| Employees | 11,000 | 66th |
Insider transactions, last 6 months
Form 4 · most recent 12| Date | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-01 | Gonzales Anita VP and CAO |
Open-market sale | 84 | $155.48 | $13,060 | 7,117 |
| 2026-09-21 | Krakowiak Maxwell Please See Remarks |
Open-market sale | 1,631 | $144.53 | $235,728 | 14,781 |
| 2026-09-16 | Vohra Tajinder S Please See Remarks |
Open-market sale | 7,330 | $140.88 | $1.0M | 6,635 |
| 2026-08-25 | Michas Alexis P Director |
Gift | 285 | — | — | 6,985 |
| 2026-08-14 | Goldberg Joel S Please See Remarks |
Gift | 27,785 | — | — | 13,729 |
| 2026-08-14 | Goldberg Joel S Please See Remarks |
Gift | 27,785 | — | — | 91,494 |
| 2026-08-13 | Singh Prahlad R. Director, Please See Remarks |
Gift | 7,636 | — | — | 105,676 |
| 2026-08-13 | Singh Prahlad R. Director, Please See Remarks |
Gift | 7,636 | — | — | 54,219 |
| 2026-08-13 | Singh Prahlad R. Director, Please See Remarks |
Gift | 59,650 | — | — | 46,026 |
| 2026-08-13 | Singh Prahlad R. Director, Please See Remarks |
Gift | 59,650 | — | — | 59,650 |
| 2026-07-20 | Gonzales Anita Vice President and CAO |
Open-market sale | 85 | $109.48 | $9,306 | 7,201 |
| 2026-06-15 | Gonzales Anita Vice President and CAO |
Tax withholding | 33 | $99.66 | $3,289 | 7,286 |
Shares acquired vs disposed, by month
acquired disposed · all Form 4 typesBy transaction type, 6 months
| Type | Direction | Filings | Shares | Value |
|---|---|---|---|---|
| Award / grant | Acquired | 18 | 20,924 | — |
| Gift | Disposed | 4 | 95,356 | — |
| Gift | Acquired | 3 | 95,071 | — |
| Open-market sale | Disposed | 5 | 9,210 | $1.3M |
| Tax withholding | Disposed | 1 | 33 | $3,289 |
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.
Form 144 notices
12 months: 10 notices · 55,670 shares · $6.0M| Filed | Filer | Shares proposed | Est. proceeds |
|---|---|---|---|
| 2026-10-01 | Gonzales Anita | 84 | $13,060 |
| 2026-09-21 | Krakowiak Maxwell | 1,631 | $235,728 |
| 2026-09-16 | Vohra Tajinder S | 7,330 | $1.0M |
| 2026-07-20 | Gonzales Anita | 85 | $9,306 |
A Form 144 is notice of a proposed sale, not a confirmed one.
Congress trades
12 months: House 10 trades (4 purchases) · Senate 0 (0 purchases)| Traded | Member | Chamber | Type | Amount | Disclosed |
|---|---|---|---|---|---|
| 2026-09-09 | Gilbert Cisneros | House | Sale | $15,001 - $50,000 | 2026-10-13 |
| 2026-09-09 | Gilbert Cisneros | House | Sale (Partial) | $15,001 - $50,000 | 2026-10-12 |
| 2026-09-04 | Gilbert Cisneros | House | Sale | $1,001 - $15,000 | 2026-10-13 |
| 2026-09-04 | Gilbert Cisneros | House | Sale (Partial) | $1,001 - $15,000 | 2026-10-12 |
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.
Largest 13F holders
Quarter to 2026-06-30, the latest most managers have filed| Manager | Shares | Value | % of shares out |
|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18,261,177 | $2.0B | 16.37% |
| Jupiter Topco LLC | 8,637,614 | $961.0M | 7.74% |
| BlackRock, Inc. | 7,658,369 | $852.1M | 6.86% |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,300,973 | $812.3M | 6.54% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 5,530,850 | $615.4M | 4.96% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,770,448 | $530.8M | 4.28% |
| STATE STREET CORP | 4,342,739 | $483.2M | 3.89% |
| VICTORY CAPITAL MANAGEMENT INC | 3,645,905 | $405.6M | 3.27% |
| DIMENSIONAL FUND ADVISORS LP | 3,428,692 | $381.5M | 3.07% |
| GEODE CAPITAL MANAGEMENT, LLC | 2,955,227 | $328.2M | 2.65% |
| MORGAN STANLEY | 2,489,866 | $277.0M | 2.23% |
| Invesco Ltd. | 2,424,970 | $269.8M | 2.17% |
| Allspring Global Investments Holdings, LLC | 2,201,041 | $248.4M | 1.97% |
| UBS Group AG | 1,863,391 | $207.3M | 1.67% |
| Pictet Asset Management Holding SA | 1,631,343 | $181.5M | 1.46% |
Institutional ownership by quarter
% of shares held by 13F filers
Number of 13F filers holding
Holder changes by quarter
| Quarter | Holders | Ownership | New | Increased | Reduced | Closed |
|---|---|---|---|---|---|---|
| None on file. | ||||||
Schedule 13D / 13G filers
| Filed | Form | Filer | % of class | Shares |
|---|---|---|---|---|
| 2026-10-07 | SCHEDULE 13G/A | T. Rowe Price Associates, Inc. | 11.8% | 13,204,725 |
| 2026-09-08 | SCHEDULE 13G/A | T. Rowe Price Investment Management, Inc. | 9.2% | 10,261,343 |
| 2026-08-14 | SCHEDULE 13G/A | T. Rowe Price Investment Management, Inc. | 16.4% | 18,269,089 |
| 2026-04-30 | SCHEDULE 13G | Vanguard Capital Management | 7.4% | 8,326,862 |
Required above 5% of a class; 13G is the passive form.
ETFs with the largest holding
| ETF | Weight in fund | Holding value |
|---|---|---|
| VITSX | 0.02% | $543.5M |
| VTI | 0.02% | $543.5M |
| VSMPX | 0.02% | $543.5M |
| VTSAX | 0.02% | $543.5M |
| VFINX | 0.03% | $447.9M |
| VFIAX | 0.03% | $447.9M |
Share structure
Shares outstanding111,586,000
Float102,493,225
Free float91.9%
Income statement
Fiscal years, USD| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $3.8B | $3.3B | $2.8B | $2.8B | $2.9B |
| Cost of revenue | $1.5B | $1.6B | $1.4B | $1.4B | $1.3B |
| Gross profit | $2.3B | $1.8B | $1.3B | $1.3B | $1.5B |
| R&D | $200.3M | $221.6M | $216.6M | $196.8M | $215.8M |
| SG&A | $741.6M | $758.0M | $706.1M | $715.3M | $945.3M |
| Operating income | $1.3B | $781.1M | $399.5M | $410.5M | $356.6M |
| EBITDA | $1.6B | $1.2B | $713.6M | $840.3M | $662.7M |
| Pretax income | $1.2B | $651.8M | $183.0M | $316.1M | $268.3M |
| Income tax | $314.1M | $139.2M | $3.5M | $33.1M | $25.8M |
| Net income | $943.2M | $569.2M | −$118.4M | $295.8M | $241.7M |
| EPS, diluted | $8.08 | $4.50 | $-0.95 | $2.41 | $2.08 |
| Diluted shares | 116.7M | 126.4M | 124.8M | 122.8M | 113.2M |
Balance sheet
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Cash & short-term investments | $603.3M | $454.4M | $1.6B | $1.2B | $919.9M |
| Receivables | $707.9M | $612.8M | $632.8M | $632.4M | $744.7M |
| Inventory | $425.9M | $405.5M | $428.1M | $367.6M | $379.5M |
| Total current assets | $2.4B | $3.3B | $3.0B | $2.3B | $2.2B |
| PP&E, net | $649.6M | $671.3M | $664.7M | $649.9M | $644.7M |
| Goodwill & intangibles | $10.4B | $9.9B | $9.6B | $9.1B | $9.0B |
| Total assets | $15.0B | $14.1B | $13.6B | $12.4B | $12.2B |
| Accounts payable | $324.8M | $272.8M | $204.1M | $167.5M | $185.5M |
| Total current liabilities | $1.2B | $1.5B | $1.5B | $653.1M | $1.3B |
| Long-term debt | $5.0B | $3.9B | $3.2B | $3.2B | $2.8B |
| Total liabilities | $7.9B | $6.7B | $5.7B | $4.7B | $4.9B |
| Shareholders' equity | $7.1B | $7.4B | $7.9B | $7.7B | $7.3B |
Cash flow statement
Outflows are negative| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Net income | $889.4M | $512.7M | $179.5M | $283.1M | $241.2M |
| Depreciation & amortization | $311.4M | $427.0M | $431.8M | $427.8M | $405.3M |
| Stock-based compensation | $29.7M | $51.5M | $41.4M | $37.8M | $22.8M |
| Change in working capital | $133.0M | −$263.0M | −$391.3M | −$18.3M | −$96.8M |
| Operating cash flow | $1.4B | $679.8M | $91.3M | $628.3M | $581.8M |
| Capital expenditure | −$86.0M | −$85.6M | −$81.4M | −$86.6M | −$73.5M |
| Free cash flow | $1.3B | $594.2M | $9.9M | $541.7M | $508.3M |
| Investing cash flow | −$4.1B | −$132.9M | $1.3B | $776.2M | −$17.4M |
| Net debt issued / repaid | $3.0B | −$559.2M | −$517.5M | −$723.1M | −$521,000 |
| Buybacks | −$73.1M | −$80.6M | −$388.9M | −$369.6M | −$820.8M |
| Dividends paid | −$32.4M | −$35.3M | −$35.0M | −$34.5M | −$32.8M |
Ratio history
Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end| FY2021 | FY2023 | FY2025 | |
|---|---|---|---|
| Gross margin | 55.0% | 52.7% | 50.2% |
| Operating margin | 31.7% | 14.5% | 13.0% |
| Net margin | 20.9% | 26.1% | 8.5% |
| FCF margin | 29.8% | 0.4% | 17.9% |
| ROE | 17.0% | 9.6% | 3.2% |
| ROIC | 8.9% | 3.8% | 3.4% |
| ROA | 8.0% | 5.2% | 1.9% |
| Debt / equity | 0.72 | 0.52 | 0.48 |
| Interest coverage | 13.2x | 2.9x | 3.9x |
| Current ratio | 2.01 | 2.07 | 1.68 |
| Revenue growth | +17.0% | −23.6% | +4.9% |
| EPS growth | +12.6% | +19.4% | −13.5% |
| P/E at year end | 27.3x | 18.7x | 45.3x |
| EV / EBITDA at year end | 18.0x | 22.3x | 17.7x |
| FCF yield at year end | 5.23% | 0.07% | 4.66% |
| Dividend payout | 3.5% | 4.9% | 13.6% |
Revenue by segment
| FY2024 | FY2025 | |
|---|---|---|
| Diagnostics | $1.5B | $1.4B |
| Life Sciences | $1.3B | $1.4B |
Revenue by region · FY2025
Other International$2.7B · 60%
UNITED STATES$1.1B · 25%
CHINA$425.1M · 9%
GERMANY$177.7M · 4%
UNITED KINGDOM$126.8M · 3%
Street estimates by fiscal year
Next report 2026-11-03 · consensus EPS $1.30 · these are analysts' numbers, not ours| Fiscal year | Revenue (mean) | Revenue range | EPS (mean) | EPS range | Analysts | P/E on mean EPS |
|---|---|---|---|---|---|---|
| 2026 | $2.9B | $2.8B – $2.9B | $5.36 | $5.35 – $5.40 | 9 | 28.5x |
| 2026 | $2.9B | $2.9B – $3.0B | $5.32 | $5.24 – $5.45 | 11 | 28.7x |
| 2027 | $3.0B | $3.0B – $3.0B | $5.89 | $5.83 – $5.92 | 9 | 25.9x |
Reported vs expected, every quarter on file
| Reported | EPS expected | EPS actual | EPS surprise | Revenue expected | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|
| 2026-08-04 | $1.21 | $1.41 | +16.5% | $703.0M | $711.0M | +1.1% |
| 2026-05-05 | $1.02 | $1.06 | +3.9% | $704.1M | $711.1M | +1.0% |
| 2026-02-02 | $1.57 | $1.70 | +8.3% | $764.9M | $772.1M | +0.9% |
| 2025-10-27 | $1.14 | $1.18 | +3.5% | $699.4M | $698.9M | −0.1% |
| 2025-07-28 | $1.14 | $1.18 | +3.5% | $699.9M | $720.3M | +2.9% |
| 2025-04-28 | $0.96 | $1.01 | +5.2% | $710.8M | $664.8M | −6.5% |
| 2025-01-31 | $1.37 | $1.42 | +3.6% | $665.3M | $729.4M | +9.6% |
| 2024-11-04 | $1.13 | $1.28 | +13.3% | $679.7M | $684.0M | +0.6% |
| 2024-07-29 | $1.12 | $1.22 | +8.9% | $690.3M | $691.7M | +0.2% |
| 2024-04-29 | $0.94 | $0.98 | +3.9% | $647.2M | $649.9M | +0.4% |
| 2024-02-01 | $1.15 | $1.25 | +8.7% | $677.9M | $695.9M | +2.6% |
| 2023-10-30 | $1.19 | $1.18 | −0.8% | $695.3M | $670.7M | −3.5% |
| 2023-08-01 | $1.18 | $1.21 | +2.5% | $696.1M | $709.1M | +1.9% |
| 2023-05-11 | $1.06 | $1.01 | −4.7% | $678.9M | $674.9M | −0.6% |
| 2023-02-14 | $1.66 | $1.70 | +2.4% | $1.0B | $741.2M | −28.0% |
| 2022-10-01 | $1.44 | $0.55 | −61.9% | $1.0B | $711.8M | −30.3% |
| 2022-07-02 | $2.01 | $1.42 | −29.4% | $1.2B | $1.2B | +2.1% |
| 2022-03-31 | $2.12 | $1.40 | −34.0% | $1.2B | $1.3B | +5.9% |
| 2021-09-30 | $2.25 | $1.11 | −50.7% | $1.3B | $1.2B | −8.4% |
Off-exchange (dark pool) volume, weekly
FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)| Week of | Notional | Shares | Trades |
|---|---|---|---|
| 2026-08-31 | $420.2M | 3,266,615 | 48,155 |
| 2026-08-24 | $236.5M | 1,878,095 | 42,451 |
| 2026-08-17 | $359.7M | 2,959,676 | 47,325 |
| 2026-08-10 | $220.4M | 1,895,071 | 41,476 |
| 2026-08-03 | $426.8M | 3,761,871 | 60,665 |
| 2026-07-27 | $399.6M | 3,576,214 | 52,917 |
Short-sale share of off-exchange volume
daily 20-day average| Date | Short share | Short volume | Total volume |
|---|---|---|---|
| 2026-10-15 | 55.6% | 706,436 | 1,269,489 |
| 2026-10-14 | 44.5% | 391,484 | 880,176 |
| 2026-10-13 | 52.8% | 303,382 | 574,950 |
| 2026-10-12 | 71.9% | 311,258 | 432,703 |
| 2026-10-09 | 58.8% | 370,675 | 630,281 |
| 2026-10-08 | 52.2% | 376,082 | 720,692 |
| 2026-10-07 | 51.6% | 510,079 | 989,276 |
| 2026-10-06 | 39.5% | 496,543 | 1,256,720 |
| 2026-10-05 | 58.9% | 365,427 | 620,658 |
| 2026-10-02 | 63.3% | 315,892 | 499,192 |
A daily flow measure from FINRA, not short interest.
Seasonality
Average return by calendar month| Month | Avg return | Up years | Years |
|---|---|---|---|
| Jan | +2.6% | 55% | 20 |
| Feb | −1.2% | 50% | 20 |
| Mar | +0.1% | 48% | 21 |
| Apr | +0.4% | 45% | 20 |
| May | +0.9% | 60% | 20 |
| Jun | +0.8% | 45% | 20 |
| Jul | +2.6% | 60% | 20 |
| Aug | −0.4% | 50% | 20 |
| Sep | +0.4% | 60% | 20 |
| Oct | −0.5% | 65% | 20 |
| Nov | +2.0% | 80% | 20 |
| Dec | +1.4% | 55% | 20 |
History, not a forecast.
Indicators
as of 2026-10-16RSI 1459.2
MFI57.1
ADX40.8
Stochastic %K / %D32.9 / 40.4
Williams %R-69.9
CCI40
TSI / signal30.4 / 35.5
Chaikin money flow0.00
ATR$5.57
Bollinger width10.6%
Volume vs 20-day avg0.52x
SupertrendUp
Moving averages and bands
level (price vs level)SMA 20$151.44 (+0.8%)
SMA 50$136.12 (+12.1%)
SMA 200$109.11 (+39.9%)
EMA 21$149.42 (+2.2%)
EMA 50$138.64 (+10.1%)
EMA 200$115.39 (+32.3%)
Bollinger upper$159.43 (−4.3%)
Bollinger lower$143.45 (+6.4%)
Parabolic SAR$164.02 (−6.9%)
Open the live chart, 110+ indicatorsAbout Revvity, Inc.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
https://www.revvity.com
Key executives
| Name | Title | Pay | Born |
|---|---|---|---|
| Prahlad R. Singh | Chief Executive Officer, President & Director | $3.6M | 1965 |
| Joel S. Goldberg | Senior Vice President of Administration, General Counsel & Secretary | $1.2M | 1969 |
| Maxwell Krakowiak | Senior Vice President & Chief Financial Officer | $1.2M | 1990 |
| Miriame Victor | Senior Vice President & Chief Business Officer | $1.0M | 1981 |
| Tajinder Vohra | Senior Vice President of Global Operations | $1.0M | 1966 |
| Bryan A. Kipp | Senior Vice President of Technology & Licensing | — | — |
| Madhuri FACMG | Senior Vice President & Chief Scientific Officer | — | — |
| Magali Four | Senior Vice President & Chief People and Culture Officer | — | — |
Executive pay, latest proxy
| Executive | Year | Salary | Stock awards | Incentive | Total |
|---|---|---|---|---|---|
| None on file. | |||||
Employees
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| 2026-10-23 | $0.07 | 2026-11-13 |
| 2026-07-17 | $0.07 | 2026-08-07 |
| 2026-04-17 | $0.07 | 2026-05-08 |
| 2026-01-16 | $0.07 | 2026-02-06 |
| 2025-10-17 | $0.07 | 2025-11-07 |
| 2025-07-18 | $0.07 | 2025-08-08 |
| 2025-04-17 | $0.07 | 2025-05-09 |
| 2025-01-17 | $0.07 | 2025-02-07 |
Moat model
Narrow · Efficient Scale · 2026-07-05Cost advantage48
Intangibles19
Switching costs82
Network effect50
Efficient scale85
Our component scores (0-100) and overall 55.1; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17